Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.